LB Pharmaceuticals Inc Common Stock

LBRX • Biotechnology

$49.34

▲ +1.82 (+3.83%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 62%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$1.39B

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.01Liquidez saludable · 41.44Rentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 12 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 13 ago 2026, 12:09 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$49.34

Change3.83%

Shares Out28.24M

Market Cap$1.39B

Enterprise Value$1.03B

52W Range13.36 - 49.14

Beta0.42

P/E-35.57

P/B3.68

P/FCF-26.95

EV/EBITDA-22.27

EV/FCF-19.89

Price$49.34

Change3.83%

Shares Out28.24M

Market Cap$1.39B

Enterprise Value$1.03B

52W Range13.36 - 49.14

Beta0.42

P/E-35.57

P/B3.68

P/FCF-26.95

EV/EBITDA-22.27

EV/FCF-19.89

Earnings Yield-2.81%

FCF Yield-3.71%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.01

Current Ratio41.44

Quick Ratio41.44

Target$51.86

Target Upside5.11%

Target Median$53.00

Target Range36.00 - 78.00

Volume353.91K

Avg Volume289.71K

EPS Surprise0.08

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

46

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

88/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.01Liquidez saludable · 41.44Rentabilidad débil

Analyst view

Analyst sentiment and price target

LBRX

Analyst sentiment

Based on 3 analyst votes · 2026-09-05

100/100

Bullish

Bullish

3

Hold

0

Bearish

0

Precio objetivo

2026-08-13

Bajo

$36.00

Promedio

$47.86

Mediana

$45.00

Alto

$78.00

Resumen de la compañía

IPO: 9/11/2025

Industria: Biotechnology

P/B i: 3.68

Deuda / Patrimonio i: 0.01

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 41.44

Ratio rápido: 41.44

Estado: Good

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

LB Pharmaceuticals Inc Common Stock

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Competidores

10

ALT ANNX AURA AUTL DBVT DSGN KRRO LRMR RCKT SLDB

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

8

LB Pharmaceuticals to Participate in Upcoming September Investor Events

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team, will present and participate in the following upcoming investor conferences:

LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Joseph Miller as Chief Financial Officer.

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride Cash, cash equivalents, and marketable securities of $327.8 million as of June 30, 2026, and proceeds from recent $150.0 million private placement to fund pipeline expansion, expected to fund operations beyond Q2 2029, through multiple clinical milestones NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced financial results for the second quarter ended on June 30, 2026 and provided a corporate update. “We are taking meaningful steps to maximize the full potential of LB-102, leveraging clinically validated biology with purposeful innovation as the foundation for an expanded pipeline,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals.

LB Pharmaceuticals Announces $150 Million Private Placement

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced that it has entered into a securities purchase agreement to sell 3,577,560 shares of its common stock and pre-funded warrants to purchase up to 715,513 shares of its common stock to a limited group of institutional investors in a private placement. The purchase price of each share of common stock is $34.94.

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-12	-0.75	-0.67	0.08
2026-03-26	-0.45	-0.45	0
2025-11-06	-0.57	-0.61	-0.04